Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huamiao, Xu, Binyue, Xu, Jili, Zhu, Guomeng, Guo, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217641/
https://www.ncbi.nlm.nih.gov/pubmed/34168990
http://dx.doi.org/10.3389/fonc.2021.670907
_version_ 1783710634003660800
author Zhou, Huamiao
Xu, Binyue
Xu, Jili
Zhu, Guomeng
Guo, Yong
author_facet Zhou, Huamiao
Xu, Binyue
Xu, Jili
Zhu, Guomeng
Guo, Yong
author_sort Zhou, Huamiao
collection PubMed
description Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs) (crizotinib then alectinib), as her imaging findings and clinical symptoms significantly improved. At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib. The adverse effects were manageable. The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion.
format Online
Article
Text
id pubmed-8217641
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82176412021-06-23 Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report Zhou, Huamiao Xu, Binyue Xu, Jili Zhu, Guomeng Guo, Yong Front Oncol Oncology Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs) (crizotinib then alectinib), as her imaging findings and clinical symptoms significantly improved. At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib. The adverse effects were manageable. The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217641/ /pubmed/34168990 http://dx.doi.org/10.3389/fonc.2021.670907 Text en Copyright © 2021 Zhou, Xu, Xu, Zhu and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Huamiao
Xu, Binyue
Xu, Jili
Zhu, Guomeng
Guo, Yong
Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title_full Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title_fullStr Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title_full_unstemmed Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title_short Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
title_sort novel mrps9-alk fusion mutation in a lung adenocarcinoma patient: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217641/
https://www.ncbi.nlm.nih.gov/pubmed/34168990
http://dx.doi.org/10.3389/fonc.2021.670907
work_keys_str_mv AT zhouhuamiao novelmrps9alkfusionmutationinalungadenocarcinomapatientacasereport
AT xubinyue novelmrps9alkfusionmutationinalungadenocarcinomapatientacasereport
AT xujili novelmrps9alkfusionmutationinalungadenocarcinomapatientacasereport
AT zhuguomeng novelmrps9alkfusionmutationinalungadenocarcinomapatientacasereport
AT guoyong novelmrps9alkfusionmutationinalungadenocarcinomapatientacasereport

Ejemplares similares